Introduction

Human papillomavirus (HPV) is responsible for nearly 1 out of every 20 cancer cases worldwide [1]. HPV-mediated cellular transformation is achieved primarily through expression of the viral E6 and E7 oncogenes. E6 and E7 act on a variety of targets to induce cell cycle progression. The most critical events for tumor development seem to be the E6-mediated degradation of the tumor suppressor p53 and induction of telomerase expression, and the E7-mediated degradation of the retinoblastoma (Rb) family of proteins [2–5]. p53 and Rb1 are important tumor suppressor proteins that play critical roles in restricting cell cycle progression and maintaining genomic stability. Consequently, E6 and E7 not only enhance cell proliferation, but also the acquisition of additional oncogenic mutations associated with a loss of genomic stability. While HPV-negative squamous cell carcinomas (SCC) usually have p53 mutations, most HPV-positive tumors are wild type for both p53 and Rb since both pathways are already inactivated by E6 and E7[6–9].

In the United States, Oropharyngeal (OSCC), Cervical (CSCC), Anal (ASCC), and Vulvar (VSCC) squamous cell carcinomas account for the largest number of new HPV-associated cancers each year [10]. Over 90% of CSCC and ASCC cases are caused by HPV and about 70% of OSCC and VSCC are the result of HPV infection [11]. The management of CSCC, OSCC, ASCC, and VSCC often includes a multimodal treatment strategy that may include chemotherapy, radiation therapy, and surgery. Importantly, platinum-based chemo-radiation protocols are similarly effective against ASCC, OSCC, CSCC, and

Comparative molecular profiling of HPV-induced squamous cell carcinomas

Robert F. Koncar1, Rebecca Feldman2, El Mustapha Bahassi1 & Nooshin Hashemi Sadraei1

1Department of Internal Medicine, Division of Hematology/Oncology, University of Cincinnati, Cincinnati, Ohio
2Caris Life Sciences, Phoenix, Arizona

Keywords
Biomarkers, DNA sequencing, HPV, molecular profiling, protein expression, squamous cell carcinoma

Abstract
Approximately 5% of all cancer incidences result from human papillomavirus (HPV) infection. HPV infection most commonly leads to cancers of the anogenital region or oropharynx. It is unknown whether different HPV-mediated cancers collectively share a molecular signature and it is important to determine if there are targetable alterations common to different types of HPV-positive tumors. We analyzed 743 p53 wild-type samples of anal, cervical, oropharyngeal, and vulvar squamous cell carcinomas which underwent multiplatform testing at a commercial molecular profiling service. Expression of 24 proteins was measured by immunohistochemistry (IHC), mutation of 48 genes was determined by next-generation and Sanger sequencing, and copy number alteration for six genes was determined by in situ hybridization. The four cohorts had remarkably similar molecular profiles. No gene had a statistically significant difference in mutation frequency or copy number change between the four different types of squamous cell carcinomas. The only significant differences between cohorts were frequency of ERCC1 and SPARC loss as determined by IHC. In all four cancer types, oncogene mutation and PD-L1 expression was relatively infrequent. The most commonly mutated gene was PIK3CA, with mutations most often affecting the helical domain of the protein and accompanied by concurrent lack of PTEN expression. Loss of MGMT and RRM1 was common among the four cohorts and may be predictive of response to cytotoxic therapies not currently being used to treat these cancer types. The similar molecular profiles of the four cohorts indicate that treatment strategies may be similarly efficacious across HPV-positive cancers.
VSCC, suggesting different HPV-positive cancers may have a common molecular signature and share the same targetable genetic alterations [12]. Tailoring customized treatment regimens based on the molecular profiling of advanced solid tumors has been successful in several early phase trials [13–15]. Therefore, we assessed CSCC, ASCC, OSCC, and VSCC for additional evidence of shared characteristics that could be used to identify potential molecular targets across the spectrum of HPV-induced cancers.

In this study, we examined biomarker frequency data collected from a commercial molecular profiling service (Caris Life Sciences, Phoenix, AZ). Since p53 mutation is rare in HPV-positive tumors, p53 status was used as a surrogate for HPV testing [16, 17]. By analyzing p53 wild type-SCC of the cervix, anal canal, oropharynx, and vulva, we sought to determine whether different HPV-positive cancers may respond to common treatment protocols and to identify targetable alterations for patients with these cancers that are advanced, refractory, and difficult to treat. Using a multiplatform approach, this analysis identified several alterations that have the potential to aid in the design of treatment regimens. Our results revealed marked similarities among the HPV-induced cancers indicating that similar treatment protocols may be beneficial to these cancer types. Importantly, this detailed examination of protein, genetic, and genomic alterations may provide insight for the design of future clinical trials.

**Methods**

**Patients and multiplatform molecular profiling**

Molecular theranostic biomarkers were assayed by immunohistochemistry, in situ hybridization, and gene sequencing. The biomarker-drug associations are determined from prospective or retrospective clinical research studies in various solid tumors or are part of the National Comprehensive Cancer Network (NCCN) Biomarkers Compendium. For some biomarkers, therapeutic associations are suggested based on emerging data (e.g., investigational agents in clinical trials). This study includes data from 743 patients with refractory, aggressive, and/or metastatic ASCC, OSCC, CSCC, or VSCC with wild-type p53. All samples were prospectively assayed by at least one platform (immunohistochemical (IHC), in situ hybridization (ISH), and/or chromogenic ISH probes with targetable alterations for patients with these cancers that are advanced, refractory, and difficult to treat. Using a multiplatform approach, this analysis identified several alterations that have the potential to aid in the design of treatment regimens. Our results revealed marked similarities among the HPV-induced cancers indicating that similar treatment protocols may be beneficial to these cancer types. Importantly, this detailed examination of protein, genetic, and genomic alterations may provide insight for the design of future clinical trials.

**Immunohistochemistry**

Immunohistochemistry (IHC) analysis of 24 proteins was performed by Caris Life Sciences on FFPE tumor samples using commercially available detection kits and automated staining techniques (Benchmark XT; Ventana Medical Systems, Tucson, AZ; and Autostainer-Link 48; Dako, Carpinteria, CA) and manually scored by board-certified pathologists. IHC analysis, antibody clones, and thresholds used are described in Table S1. IHC for p16 was performed by the Cincinnati Children’s Hospital pathology core using antibody clone E6H4 (Ventana Medical Systems, Tucson, AZ) and positivity was determined by the authors.

**In situ hybridization**

c-MET, c-MYC, EGFR, HER2, PIK3CA, and TOP2A gene copy number alterations were analyzed using fluorescence in situ hybridization (ISH) and/or chromogenic ISH probes as part of the automated staining techniques (Benchmark XT; Ventana Medical Systems) and automated imaging systems (BioView, Billerica, MA). Copy number alteration was determined as previously described [9].

**Sanger sequencing**

Sanger sequencing included selected regions of BRAF, c-KIT, EGFR, KRAS, NRAS, and PIK3CA and was performed using M13-linked polymerase chain reaction primers designed to flank and amplify targeted sequences. Polymerase chain reaction products were bidirectionally sequenced using the BigDye Terminator version 1.1 chemistry, and analyzed using the 3730 DNA Analyzer (Applied Biosystems, Grand Island, NY). Sequence traces were analyzed using Mutation Surveyor software version 3.25 (Soft Genetics, State College, PA).

**Next-generation sequencing**

NGS was performed on gDNA from FFPE tumor tissue using the Illumina MiSeq. Specific regions of 48 genes were amplified with the Illumina TruSeq Amplicon Cancer Hotspot panel. All reported mutations were detected with over 99% confidence with an average sequencing depth of over 1000×.

**Statistical methods**

Retrospective analysis of biomarker frequency was determined using standard descriptive statistics. The two-tailed
Fisher’s exact test was performed using JMP version 10.0 (SAS Institute, Cary, NC) to test where frequencies differed among cohorts. Bonferroni correction was used to correct for multiple comparisons. A corrected two-tailed \( P \) value \( \leq 0.05 \) was determined statistically significant.

**Validation and institutional review board**

All methods utilized in this study were clinically validated to Clinical Laboratory Improvement Amendments, College of American Pathologists, and International Organization for Standardization (ISO) 15,189. This retrospective analysis utilized previously collected, de-identified data created under the Caris honestbroker policy and followed consultation with the Western Institutional Review Board (IRB), which is the IRB of record for Caris Life Sciences. The project was determined to be exempt from IRB oversight and consent requirements were waived.

**Results**

**Patient and Tumor characteristics**

ASCC, CSCC, OSCC, and VSCC tumors were screened for p53 status as a surrogate for HPV testing. A total of 743 tumors with wild-type p53 status were identified for this study and are described in Table 1. While over 90% of all ASCC and CSCC cases result from HPV infection, only 70% of OSCC cases are HPV positive and tobacco or alcohol use likely contribute to the other 30% [11, 18]. To further validate that the cohorts contained HPV-positive samples, OSCC tissue was also tested for p16 immunoreactivity, which is a reliable, clinically utilized indicator of HPV positivity [19]. Of the 147 p53 wild-type OSCC specimens, 128 had slides of tissue available for p16 IHC. Over 97% of the OSCC samples tested (125/128) were positive for p16 expression (Table S2). CSCC samples accounted for approximately 42\% (\( n = 314 \)) of all tumors. ASCC, OSCC, and VSCC accounted for 27\% (\( n = 199 \)), 20\% (\( n = 147 \)), and 11\% (\( n = 83 \)) of samples, respectively. The ASCC cohort was predominantly female (64\%), while the male sex made up the majority of the OSCC cohort (84\%). Of the 743 tumor samples, 337 (45\%) were from primary tumors and 406 (55\%) were metastatic.

**Gene expression and copy number alteration**

Total rates of gene expression as measured by IHC and gene copy number alteration by ISH are listed in Table 2. Only biomarkers that had been tested in all four types of SCC were included in further analysis. Therefore, IHC testing of BCRP, c-kit, COX-2, and MRP1 as well as ISH testing of c-MYC and PIK3CA were not compared across types of SCC since there were no data from one or more SCC cohorts (Fig. 1).

| Table 1. Clinicopathological characteristics of 743 patients with molecularly profiled p53 wild-type squamous cell carcinoma. |
|-------------------|----------------|----------------|----------------|----------------|
|                   | ASCC           | CSCC           | OSCC           | VSCC           |
| Male (%)          | 70 (35.2\%)    | 0 (0\%)        | 124 (84.4\%)   | 0 (0\%)        |
| Average age, years| 59             | N/A            | 58             | N/A            |
| Minimum age       | 31             | N/A            | 27             | N/A            |
| Maximum age       | 88             | N/A            | 88             | N/A            |
| Site of tumor profiled (%) | | | | |
| Primary site      | 28 (40\%)      | N/A            | 67 (54\%)      | N/A            |
| Metastatic site   | 42 (60\%)      | N/A            | 57 (46\%)      | N/A            |
| Female (%)        | 129 (64.8\%)   | 314 (100\%)    | 23 (15.6\%)    | 83 (100\%)     |
| Average age, years| 59             | 50             | 61             | 61             |
| Minimum age       | 35             | 24             | 26             | 29             |
| Maximum age       | 89             | 90             | 79             | 85             |
| Site of tumor profiled (%) | | | | |
| Primary site      | 36 (27.9\%)    | 141 (45\%)     | 15 (65.2\%)    | 50 (60.2\%)    |
| Metastatic site   | 93 (72.1\%)    | 173 (55\%)     | 8 (34.8\%)     | 33 (39.8\%)    |
| Total             | 199            | 314            | 147            | 83             |
| Site of tumor profiled (%) | | | | |
| Primary site      | 64 (32.2\%)    | 141 (45\%)     | 82 (55.8\%)    | 50 (60.2\%)    |
| Metastatic site   | 135 (67.8\%)   | 173 (55\%)     | 65 (44.2\%)    | 33 (39.8\%)    |
IHC revealed the most frequently altered proteins to be: TOP2A (94.7%), EGFR (93%), MRP1 (89.2%), and PD-1 (73.3%), which were all highly expressed. Loss of MGMT (66.8%), TS (66.7%), and PTEN (59.4%) expression also occurred at high frequency. ISH showed the PIK3CA and c-MYC genes were amplified in 100% and 25% of tested samples, respectively. However, only three patients were tested for PIK3CA and only four patients were tested for c-MYC amplification. No other amplifications were detected at high rates. The only other amplifications detected were EGFR, HER2, and c-MET which occurred in less than 10% of tested samples.

Markedly similar expression profiles were detected between ASCC, CSCC, OSCC, and VSCC (Fig. 1A). In all four cohorts, IHC most commonly revealed high expression of EGFR, which ranged from detection rates of 89.8% in CSCC to 97.9% in OSCC, and TOP2A, which ranged from detection rates of 86.5% in VSCC to 98.4% in OSCC. While EGFR detection was common, ALK expression was not detected in any of the cohorts. The biomarker with the largest variance of detection among the four types of SCC was SPARC P. Over 42% of CSCC samples were positive for SPARC P (P < 0.001), while only 13.7% of OSCC samples were positive (P < 0.001).

ERCC1 expression was lost in over half of ASCC samples and over 43% of OSCC and VSCC samples. However, only 26.5% of CSCC samples lost ERCC1 expression (P = 0.024). MRP1 was detected at high frequency in ASCC (97.7%), OSCC (86.2%), and VSCC (79.3%) though no cases of CSCC were tested for MRP1 by IHC. The detection rates of RRM1 and TLE3 expression were also consistent across cohorts and ranged from 56% to 66% and 42% to 52%, respectively. Loss of PTEN, MGMT, and TS expression was also consistent among all four groups. Rates of PTEN loss ranged from 56% to 66% and 42% to 52%, respectively. Loss of PTEN, MGMT, and TS expression was also consistent among all four groups. Rates of PTEN loss ranged from 56% to 66% and 42% to 52%, respectively. Loss of PTEN, MGMT, and TS expression was also consistent among all four groups. Rates of PTEN loss ranged from 56% to 66% and 42% to 52%, respectively. Loss of PTEN, MGMT, and TS expression was also consistent among all four groups. Rates of PTEN loss ranged from 56% to 66% and 42% to 52%, respectively. Loss of PTEN, MGMT, and TS expression was also consistent among all four groups. Rates of PTEN loss ranged from 56% to 66% and 42% to 52%, respectively. Loss of PTEN, MGMT, and TS expression was also consistent among all four groups. Rates of PTEN loss ranged from 56% to 66% and 42% to 52%, respectively.

The PD-1/PD-L1 immunomodulatory axis was also evaluated across the four cohorts of SCC. Tumor infiltrating lymphocytes were examined for PD-1 expression and tumor cells were tested for PD-L1 expression. Positivity for PD-1 was more common than for PD-L1. Rates of

| Method          | Biomarker | Number of samples tested | Number of samples altered | % altered |
|-----------------|-----------|--------------------------|---------------------------|-----------|
| IHC (high expression) | ALK       | 123                      | 0                         | 0.0       |
|                 | AR        | 648                      | 29                        | 4.5       |
|                 | BCRP      | 9                        | 1                         | 11.1      |
|                 | c-kit     | 104                      | 2                         | 1.9       |
|                 | c-MET     | 538                      | 84                        | 15.6      |
|                 | COX-2     | 10                       | 3                         | 30.0      |
|                 | EGFR      | 273                      | 254                       | 93.0      |
|                 | ER        | 680                      | 104                       | 15.3      |
|                 | HER2      | 700                      | 13                        | 1.9       |
|                 | MRP1      | 102                      | 91                        | 89.2      |
|                 | PD-1      | 326                      | 239                       | 73.3      |
|                 | PD-L1 (SP142) | 368              | 81                        | 22.0      |
|                 | PGP       | 588                      | 11                        | 1.9       |
|                 | PR        | 677                      | 23                        | 3.4       |
|                 | RRM1      | 596                      | 386                       | 64.8      |
|                 | SPARC M   | 506                      | 146                       | 28.9      |
|                 | SPARC P   | 546                      | 170                       | 31.1      |
|                 | TLE3      | 548                      | 248                       | 45.3      |
|                 | TOP2A     | 661                      | 626                       | 94.7      |
|                 | TOPO1     | 679                      | 443                       | 65.2      |
| IHC (low/no expression) | ERCC1   | 296                      | 122                       | 41.2      |
|                 | MGMT      | 669                      | 447                       | 66.8      |
|                 | PTEN      | 694                      | 412                       | 59.4      |
|                 | TS        | 690                      | 460                       | 66.7      |
|                 | TUBB3     | 571                      | 138                       | 24.2      |
| ISH (amplification) | c-MET    | 421                      | 1                         | 0.2       |
|                 | c-MYC     | 4                        | 1                         | 25.0      |
|                 | EGFR      | 85                       | 7                         | 8.2       |
|                 | HER2      | 574                      | 13                        | 2.3       |
|                 | PIK3CA    | 3                        | 3                         | 100.0     |
|                 | TOP2A     | 33                       | 0                         | 0.0       |
PD-1 expression positivity ranged from 63.3% in ASCC to 80.6% in OSCC, while PD-L1 expression positivity rates ranged from only 13.3% in VSCC to 24.9% in CSCC.

Only c-MET, EGFR, HER2, and TOP2A were examined for gene copy number alterations in samples from all four cohorts. Gene amplification was found by ISH to be an uncommon event, regardless of cancer type (Fig. 1B). The most commonly amplified gene was EGFR which was amplified in 9.1% of OSCC, 8.1% of ASCC, 8% of VSCC, and 0% of CSCC cases. Amplification of c-MET was detected only in a single case of VSCC (2.3%), while TOP2A amplification was not found in any samples. PIK3CA amplification was examined in only two cases of ASCC and one case of OSCC, all of which tested positive, while c-MYC copy number increase was detected in one of three tested OSCC samples and was not amplified in the one ASCC sample tested.

**Mutation analysis**

Total rates of variant detection for the 47 genes analyzed for mutation are shown in Table 3. Specific allele changes are listed in Table S3 and mutation profiles by patient are listed in Table S4. The most frequently mutated gene was PIK3CA which was altered in 25.8% of SCC patients tested. The next most commonly mutated genes were FBXW7 (6.4%) and PTEN (3.2%). No known oncogenic mutations were detected in the following genes in any of the four cohorts: ABL1, ALK, BRAF, CDH1, c-KIT, c-MET, CSF1R, EGFR, ERBB2, ERBB4, FGFR1, FGFR2, FLT3, GNA11, GNAQ, IDH1, JAK2, JAK3, KDR, MLH1, MPL, NOTCH1, NPM1, PDGFR, PTPN11, RET, SMARCB1, SMO, and VHL (Table 3).

PIK3CA was the most commonly mutated gene in all four types of SCC, occurring at a rate of 24.8% in ASCC, 30.5% in CSCC, 22.3% in OSCC, and 10.2% in VSCC (Fig. 2). Other than PIK3CA mutation, mutational events were relatively uncommon in all four cohorts. The next most commonly mutated gene in ASCC and OSCC was AKT1 (12%). However, only 3% of CSCC samples were mutant and no FBXW7 mutations were detected in VSCC samples. The second most common mutation in VSCC was BRCA2 (6.7%), which was not detected in ASCC or OSCC and found in only 1.5% of CSCC cases. The only gene found mutated within all four cohorts, aside from PIK3CA, was AKT1, albeit at a very low rate (0.8%-5.5%). No differences in mutation rates were statistically significant between the four cohorts.

**PI3K pathway**

Phosphoinositide 3-kinase (PI3K) is a heterodimer lipid kinase that, when activated by a receptor tyrosine kinase, converts PIP2 to PIP3 [20]. The p110α catalytic subunit of the enzyme is encoded by the PIK3CA gene. PIP3 recruits AKT to the membrane, where it can be activated and promote proliferation, growth, and survival through activation of downstream targets such as mTOR. The phosphatase PTEN acts antagonistically to PI3K, dephosphorylating PIP3 to PIP2, and preventing AKT recruitment and activation [21, 22].
The specific site of a PIK3CA mutation is potentially an important predictive indicator for tumor growth and response to treatment. In urothelial carcinoma, mutations in the kinase domain of the protein result in increased AKT activation, compared to helical domain mutations [23]. Additionally, specific PIK3CA mutations may have implications for treatment efficacy. Patients with advanced solid tumors harboring an H1047R mutation, which is in the kinase domain, benefit from treatment with a PI3K/AKT/mTOR inhibitor more than patients with other PIK3CA mutations [24]. Examination of specific PIK3CA mutation loci revealed that all four types of SCC had similar distributions of mutation sites within the PIK3CA gene (Fig. 3A). In each of the four cohorts, E545 was the most commonly mutated site and a missense mutation at either E542 or E545 in the helical domain of the protein accounted for 75% of all PIK3CA mutations. Mutations in the kinase domain were not common as they accounted for 12% of the PIK3CA mutations for OSCC and ASCC. In CSCC, only 7% of PIK3CA mutations were in the kinase domain and none were detected in VSCC. However, there were only five cases of PIK3CA-mutant VSCC in the study. Interestingly, mutation of E726 in exon 13, which is of unknown clinical significance, was detected in all four cohorts.

PI3 kinase inhibitors are currently in clinical trials and loss of PTEN expression has emerged as an indicator of resistance to PI3K inhibition [25]. It was previously reported that 24% of head and neck SCC with a PI3K mutation also exhibit loss of PTEN expression [9]. HPV-positive tumors exhibited much higher rates of co-occurrence in all four cohorts (Fig. 3B). In PIK3CA-mutant samples, concurrent PTEN loss was found in 82.4% (ASCC), 80% (VSCC), 66.3% (CSCC), and 56.5% (OSCC) of cases.

PIK3CA mutation status and PTEN expression was then examined based on disease state for each of the four SCCs. Disease state was classified depending upon whether the sample was collected from the primary tumor, regional metastasis into the surrounding soft tissue, lymph node, or distant metastasis. PIK3CA mutation rate in ASCC ranged from 20% in specimens from the primary tumor site to 37% in samples from regional metastases (Fig. 3C). The mutation rate in CSCC ranged from 25% in distant metastases to 34% in regional metastases. OSCC mutation rates were lowest in tissue from the primary tumors (16%) and highest in samples collected from the lymph nodes (44%). VSCC had the widest range of PIK3CA mutation rates with no mutations detected in regional metastases, while the only sample from a case of distant metastasis

Figure 1. HPV-positive squamous cell carcinomas have similar rates of expression profile alteration. (A) IHC revealed similar rates of biomarker detection in ASCC, CSCC, OSCC, and VSCC tumors. Positivity is indicative of high expression unless denoted. # indicates low or no expression as positive. (B) Frequency of gene amplification across SCCs as determined by ISH. P < 0.05 (*); P < 0.001 (**).
was positive for \textit{PIK3CA} mutation. Only 47 VSCC samples could be included for comparison of \textit{PIK3CA} mutation by disease state and of these, only three were of regional metastases. No differences were statistically significant after correction for multiple comparisons.

\textit{PIK3CA}-mutant samples stratified by disease state were also examined for concurrent loss of PTEN (Fig. 3D). In cases of \textit{PIK3CA}-mutant ASCC, PTEN loss was detected in 77% of samples from regional metastases, 83% of distant metastases, 90% of primary tumors, and 100% of samples from lymph nodes. For CSCC, \textit{PIK3CA}-mutant samples from lymph nodes had the lowest rate of PTEN loss (63%), while samples from regional metastases had the highest (82%). OSCC samples ranged from 50% in lymph node samples to 67% in samples from regional and distant metastases. \textit{PIK3CA}-mutation was not detected in any VSCC samples of regional metastases; so, concurrent PTEN loss could not be examined. Rates of PTEN loss ranged from 50% in primary tumor samples to 100% in samples from lymph nodes and distant metastases. Despite the wide range of PTEN loss rates in VSCC, there were only five total \textit{PIK3CA}-mutant samples and no differences were statistically significant.

**PD-1/PD-L1**

With the emergence of anti-PD-1 therapies, PD-L1 has become an important biomarker in an attempt to predict what patients would benefit from anti-PD-1 treatments [26]. In all four cohorts, PD-1 expression on tumor infiltrating lymphocytes (TIL) was much more common than PD-L1 expression on tumor cells (Fig. 1). PD-1 and PD-L1 expression were analyzed by disease state for each type of SCC (Fig. 4A, B). In ASCC, PD-1 positivity on TIL ranged from 40% in samples from lymph nodes to 75% in regional metastases. For CSCC, PD-1 positivity was more common in primary tumors (79.7%) and regional metastases (77.8%) than in samples from lymph nodes (57.8%) and distant metastases (59.1%). Over 90% of OSCC samples from primary tumors and lymph nodes were positive for TIL expression of PD-1. Positivity rates for regional and distant metastases were 66.7% and 54.5%, respectively. Two out of two VSCC samples from regional metastases tested for PD-1 were positive for expression on TIL, while neither of the two samples tested from distant metastases were positive. VSCC samples from primary tumors had the lowest rate of positivity (68.5%) and lymph nodes (88%) were similar in terms of PD-1 expression. No differences in PD-1 expression were statistically significant. Additionally, there was not a statistically significant difference in PD-1 expression between primary and metastatic tumors in general (Fig. S1).

Tumor cell expression of PD-L1 was also tested. Within primary tumors and regional metastases, PD-L1 expression was similar in the different types of SCC. In primary tumors, PD-L1 expression was most common in CSCC (26.7%) and least common in OSCC (14.7%). In regional metastases, ASCC, CSCC, and OSCC positivity rates ranged from 10% (ASCC) to 23.9%. No VSCC samples of regional metastases were positive for PD-L1 expression, though only three samples were tested. None of the nine VSCC samples from lymph nodes or two samples from distant metastases were positive for PD-L1 expression. Rates of positivity within lymph node samples were 20% (ASCC), 12.5% (CSCC), and 36.4% (OSCC). For distant metastases, none of the 11 OSCC samples tested were positive for PD-L1 expression. ASCC and CSCC samples had positivity rates of 10% and 29.1%, respectively. No differences in rates of PD-L1 expression were statistically significant.
**Discussion**

All four types of SCC showed a strikingly similar molecular profile. Chemotherapeutic treatment options are similar for ASCC, CSCC, OSCC, and VSCC with 5-fluorouracil and platinum-based therapies commonly used across all four types of cancer. However, CSCC currently has more treatment options than the other three types of SCC evaluated (Table 4). The similarities between the four cohorts suggest that treatments shown to be effective in HPV-positive CSCC may also be beneficial in the treatment of ASCC, OSCC, and VSCC. Low RRM1 expression is used to predict gemcitabine efficacy in CSCC (Table 4) and is common in all four cohorts (Fig. 1A), suggesting gemcitabine may be beneficial beyond just CSCC. Taxanes are currently used to treat CSCC, OSCC, and VSCC and are currently in clinical trials for use in ASCC, where the results are very promising, particularly in HPV-positive cases [27].

In addition to cytotoxic agents, targeted therapies such as the anti-EGFR antibody, cetuximab, are also being used. However, there are currently no recognized biomarkers to predict which patients will benefit from these treatments [28] (Table 4). While, EGFR amplification was not common, the vast majority of samples in all four cohorts highly expressed EGFR. Surprisingly, EGFR copy number

---

**Figure 3.** Different HPV+ squamous cell carcinomas have similar PIK3CA mutational landscapes. (A) Frequency and distribution of mutations within the PIK3CA gene as determined by NGS and Sanger sequencing. Corresponding protein domains are shown below the graph. (B) Percent of PIK3CA-mutant tumors with co-occurring loss of PTEN as determined by IHC. (C) Percent of samples with PIK3CA mutation stratified by disease state. For primary tumors, \( n = 50 \) (ASCC), \( n = 113 \) (CSCC), \( n = 56 \) (OSCC), \( n = 29 \) (VSCC). For regional metastases, \( n = 35 \) (ASCC), \( n = 85 \) (CSCC), \( n = 12 \) (OSCC), \( n = 3 \) (VSCC). For samples from lymph nodes, \( n = 11 \) (ASCC), \( n = 25 \) (CSCC), \( n = 9 \) (OSCC), \( n = 14 \) (VSCC). For distant metastases, \( n = 27 \) (ASCC), \( n = 32 \) (CSCC), \( n = 13 \) (OSCC), \( n = 1 \) (VSCC). (D) Percent of PIK3CA-mutant samples with co-occurring loss of PTEN expression. For primary tumors, \( n = 10 \) (ASCC), \( n = 32 \) (CSCC), \( n = 8 \) (OSCC), \( n = 2 \) (VSCC). For regional metastases, \( n = 13 \) (ASCC), \( n = 28 \) (CSCC), \( n = 3 \) (OSCC), \( n = 0 \) (VSCC). For samples from lymph nodes, \( n = 2 \) (ASCC), \( n = 8 \) (CSCC), \( n = 4 \) (OSCC), \( n = 2 \) (VSCC). For distant metastases, \( n = 6 \) (ASCC), \( n = 7 \) (CSCC), \( n = 3 \) (OSCC), \( n = 1 \) (VSCC). No differences were statistically significant after correcting for multiple comparisons.
The rate of EGFR IHC positivity in our OSCC cohort is higher than reported in other HPV-positive OSCC cohorts [38–40]. This is likely because our data are generated from samples submitted to a commercial molecular profiling service. Samples from tumors that respond well to chemotherapy are unlikely to be submitted for molecular profiling and consequently, our cohort may contain a disproportionately high number of aggressive, treatment-resistant tumors that have already been treated with chemotherapy. EGFR expression is associated with a poor prognosis in OSCC [38], further suggesting that our data describe the molecular profile of aggressive, treatment-resistant HPV-positive SCC, rather than HPV-positive SCC in general.

IHC positivity was even more common for TOP2a than for EGFR. In hepatocellular carcinoma, TOP2a overexpression is associated with chemoresistance. However, there is some evidence that etoposide may be beneficial to these patients in combination with doxorubicin, another topoisomerase II inhibitor [41]. In a mouse model of lymphoma, high TOP2a expression is an indicator of doxorubicin efficacy, while low TOP1 expression is associated with resistance to the topoisomerase I inhibitor camptothecin and increased responsiveness to doxorubicin [42]. Multiple studies have found that TOP1 expression level is predictive of whether colon cancer patients will benefit from irinotecan [43, 44] and possibly predictive of oxaliplatin efficacy [43]. Interestingly, while TOP1 expression level has shown great predictive value, TOP1 copy number was not found to be a predictive biomarker for irinotecan [44]. There have been several reports of using irinotecan and cetuximab as a successful combination therapy for ASCC, particularly in KRAS wild-type patients [45, 46]. These reports are in agreement with our finding that the majority of ASCC patients have high expression of both EGFR and TOP1, while also highlighting the potential importance of using biomarkers downstream of EGFR to predict the benefits of cetuximab. It remains to be seen if treatment regimens targeting EGFR and topoisomerase I are effective in CSGC, VSCC, and OSCC, but the similarities we have found between the four cohorts provides rationale for further investigation.

While we found TOP2a to be highly expressed in almost all cases of CSGC, in a trial of CSGC patients, orally administered etoposide as a second-line therapy was only effective in 11% of patients [47], indicating that TOP2a expression status alone may not be predictive of response to topoisomerase II poisons. This is not unexpected considering that most patients in this study had high expression of both TOP2a and TOP1.

In hepatocellular carcinoma, TOP2a overexpression is associated with chemoresistance. However, there is some evidence that etoposide may be beneficial to these patients.
in combination with doxorubicin, another topoisomerase II inhibitor [41]. In a mouse model of lymphoma, high TOP2a expression is an indicator of doxorubicin efficacy, while low TOP1 expression is associated with resistance to the topoisomerase I inhibitor camptothecin and increased responsiveness to doxorubicin [42]. Multiple studies have found that TOP1 expression level is predictive of whether a colon cancer patient will benefit from irinotecan [43, 44] and possibly predictive of oxaliplatin efficacy [43]. Interestingly, while TOP1 expression level has shown great predictive value, TOP1 copy number was not found to be a predictive biomarker for irinotecan [44].

High expression of the nucleotide excision repair and DNA interstrand crosslink repair protein, ERCC1, is an established marker for resistance to platinum-based chemotherapy [48–50]. Over 40% of samples in this study displayed low ERCC1 expression. ERCC1 also seems to be necessary for homologous recombination, suggesting PARP inhibitors may provide additional therapeutic benefit to these patients [51]. In vitro work suggests that the addition of a PARP inhibitor to a platinum-based treatment strategy may be beneficial when tumors have low ERCC1 expression [52].

The majority of samples in all four cohorts displayed low MGMT expression. Loss of MGMT expression is an established indicator of response to the DNA methylating agent, temozolomide. While previous studies found that temozolomide offers little value outside of treating brain tumors, most studies did not select patients based on MGMT status [53]. The use of MGMT as a biomarker for determining temozolomide utility outside of brain tumors has shown promise in case reports of colorectal cancer patients with low MGMT expression [54]. Further investigation is needed to determine if MGMT is a useful indicator of response to temozolomide in HPV-positive SCC.

Tumors expressing PD-L1 are thought to have a better chance of responding to anti-PD-1 therapy, while the value of PD-1 expression is less clear. Additional factors may play into determining the benefit of anti-PD-1 therapy, since some patients testing negative for PD-L1 have benefited greatly from immune checkpoint inhibitors [26, 55–58]. Additional work is needed to determine the predictive value of PD1 and PD-L1, specifically in HPV-induced SCC. Immunotherapies may be particularly important for treating this type of cancer since there are few targeted therapies available as options for these patients (Table 4). Furthermore, most PIK3CA mutations in these tumors occur outside of the kinase domain and are accompanied by concurrent loss of PTEN expression (Fig. 3), making these tumors potentially poor responders to PI3K inhibitors and further highlighting the importance of determining the predictive value of PD-1 and PD-L1 with regard to anti-PD1 therapy.

The similar molecular profiles of the four cohorts indicate that treatment strategies may be similarly efficacious across HPV-positive cancers. The low rate of oncogene mutation detected in the tumor samples suggests that there is limited potential for targeted therapies in HPV-positive SCC and emphasizes the importance of identifying reliable biomarkers for current and future cytotoxic and immunotherapies.

Acknowledgments
The authors thank Jamie Tweedle from the University of Cincinnati, Department of Internal Medicine for the critical reading of this manuscript.

Conflict of Interest
Rebecca Feldman is employed by Caris Life Sciences as a research scientist for the medical affairs team.

References
1. Bosch, F. X., T. R. Broker, D. Forman, A.-B. Moscicki, M. L. Gillison, J. Doorbar, et al. 2013. Comprehensive

---

Table 4. Comparison of cancer agents according to NCCN guidelines for HPV-induced cancers.

| Drug Type     | Predictive Biomarkers | ASCC                  | CSCC                      | OSCC                      | VSCC                      |
|---------------|-----------------------|-----------------------|---------------------------|---------------------------|---------------------------|
| Cytotoxic Therapies | ERCC1, BRCA1/2      | cisplatin             | cisplatin, carboplatin    | cisplatin, carboplatin    | cisplatin, carboplatin    |
|               | T5                    | 5-fluorouracil,       | 5-fluorouracil,           | 5-fluorouracil,           | 5-fluorouracil,           |
|               |                       | capcitabine           | paclitaxel,               | paclitaxel,               | paclitaxel,               |
|               |                       |                       | docetaxel,                | docetaxel,                | docetaxel,                |
|               |                       |                       | vinorelbine,              | vinorelbine,              | vinorelbine,              |
|               |                       |                       | topotecan,               | topotecan,               | topotecan,               |
|               |                       |                       | irinotecan,              | irinotecan,              | irinotecan,              |
|               |                       |                       | gemcitabine              | gemcitabine              | gemcitabine              |
|               |                       |                       | bevacizumab              | bevacizumab              | bevacizumab              |
|               |                       |                       | cetuximab                | cetuximab                | cetuximab                |
| Targeted Therapies | BRCA1/2               | mitomycin-C           | mitomycin-C              | mitomycin-C              | mitomycin-C              |
|               | none identified       |                       |                           |                           |                           |
control of human papillomavirus infections and related diseases. Vaccine 31(Suppl 7):H1–H31.
2. Shamanin, V. A., P. Sekaric, and E. J. Androphy. 2008. hAdA3 degradation by papillomavirus type 16 E6 correlates with abrogation of the p14ARF-p53 pathway and efficient immortalization of human mammary epithelial cells. J. Virol. 82:3912–3920.
3. Galloway, D. A., L. C. Gewin, H. Myers, W. Luo, C. Grandori, R. A. Katzenellenbogen, et al. 2005. Regulation of telomerase by human papillomaviruses. Cold Spring Harb. Symp. Quant. Biol. 70:209–215.
4. Felsani, A., A. M. Mileo, and M. G. Paggi. 2006. Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins. Oncogene 25:5277–5285.
5. Doorbar, J., N. Egawa, H. Griffin, C. Kranjec, and I. Murakami. 2015. Human papillomavirus molecular biology and disease association. Rev. Med. Virol. 25(Suppl 1):2–23.
6. Weinberger, P. M., Z. Yu, B. G. Haffty, D. Kowalski, M. Harigopal, J. Brandsma, et al. 2006. Molecular classification identifies a subset of human papillomavirus–associated oropharyngeal cancers with favorable prognosis. J. Clin. Oncol. 24:736–747.
7. Seiwer, T. Y., Z. Zuo, M. K. Keck, A. Khattri, C. S. Pedamallu, T. Stricker, et al. 2015. Integrated and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin. Cancer Res. 21:632–641.
8. Wrede, D., J. A. Tidy, T. Crook, D. Lane, and K. H. Vousden. 1991. Expression of RB and p53 proteins in HPV-negative and HPV-positive cervical carcinoma cell lines. Mol. Carcinog. 4:171–175.
9. Feldman, R., Z. Gatalica, J. Knetsz, S. Reddy, C.-A. Nathan, N. Javadi, et al. 2015. Molecular profiling of head and neck squamous cell carcinoma. Head Neck 38(Suppl 1):E1623–E1638.
10. Jemal, A., E. P. Simard, C. Dorell, A.-M. Noone, L. E. Markowitz, B. Kohler, et al. 2013. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring current and 9-valent HPV vaccines. J. Natl Cancer Inst. 107:djv086.
11. Saraiya, M., E. R. Unger, T. D. Thompson, C. F. Lynch, B. Y. Hernandez, C. W. Lyu, et al. 2015. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J. Natl Cancer Inst. 107: djv086.
12. Comprehensive Cancer Information - National Cancer Institute [Internet]. [cited 2016 Jun 5]; Available from: http://www.cancer.gov/
13. Von Hoff, D. D., J. J. Stephenson, P. Rosen, D. M. Loesch, M. J. Borad, S. Anthony, et al. 2010. Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J. Clin. Oncol. 28:4877–4883.
14. Tsimberidou, A.-M., S. Wen, D. S. Hong, J. J. Wheler, G. S. Falchook, S. Fu, et al. 2014. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin. Cancer Res. 20:4827–4836.
15. Wheler, J. J., F. Janku, A. Naing, Y. Li, B. Stephen, R. G. Zinner, et al. 2016. Cancer therapy directed by comprehensive genomic profiling: a single center study. Cancer Res. 76:3690–3701.
16. Tommasino, M., R. Accardi, S. Caldeira, W. Dong, I. Malanchi, A. Smet, et al. 2003. The role of TP53 in Cervical carcinogenesis. Hum. Mutat. 21:307–312.
17. Gillisson, M. L., W. M. Koch, R. B. Capone, M. Spafford, W. H. Westra, L. Wu, et al. 2000. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl Cancer Inst. 92:709–720.
18. Majchrzak, E., B. Szybiak, A. Wegner, P. Pienkowski, J. Pazdrowski, L. Luczewski, et al. 2014. Oral cavity and oropharyngeal squamous cell carcinoma in young adults: a review of the literature. Radiol. Oncol. 48:1–10.
19. Langendijk, J. A., and A. Psyrri. 2010. The prognostic significance of p16 overexpression in oropharyngeal squamous cell carcinoma: implications for treatment strategies and future clinical studies. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 21:1931–1934.
20. Engelman, J. A., J. Luo, and L. C. Cantley. 2006. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7:606–619.
21. Yuan, T. L., and L. C. Cantley. 2008. PI3K pathway alterations in cancer: variations on a theme. Oncogene 27:5497–5510.
22. Zhang, S., and D. Yu. 2010. PI(3)King apart PTEN’s role in cancer. Clin. Cancer Res. 16:4325–4330.
23. Ross, R. L., J. M. Ashkan, and M. A. Knowles. 2013. PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs. Oncogene 32:768–776.
24. Janku, F., J. J. Wheler, A. Naing, G. S. Falchook, D. S. Hong, V. M. Stepanek, et al. 2013. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 73:276–284.
25. Juric, D., P. Castel, M. Griffith, O. L. Griffith, H. H. Won, H. Ellis, et al. 2015. Convergent loss of PTEN and a subset of head and neck cancers. J. Natl Cancer Inst. 92:709–720.
26. Patel, S. P., and R. Kurzrock. 2015. PD- L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther. 14:847–856.
27. Kim, S., M. Jary, L. Mansi, B. Benzidane, A. Cazorla, M. Demarchi, et al. 2013. DCF (docetaxel, cisplatin and
5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. Ann. Oncol. 24:3045–3050.

28. National Comprehensive Cancer Network. 2016. The NCCN Biomarkers Compendium (NCCN Compendium). Available at: http://www.nccn.org/professionals/biomarkers/content/.

29. Licitra, L., R. Mesia, F. Rivera, E. Remenár, R. Hitt, J. Erfán, et al. 2011. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann. Oncol. 22:1078–1087.

30. Pirker, R., J. R. Pereira, J. von Pawel, M. Krzakowski, R. Ramlau, K. Park, et al. 2012. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 13:33–42.

31. Licitra, L., S. Störkel, K. M. Kerr, E. Van Cutsem, R. Pirker, F. R. Hirsch, et al. 2013. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur. J. Cancer 49:1161–1168.

32. Bertotti, A., E. Papp, S. Jones, V. Adleff, V. Anagnostou, B. Lupo, et al. 2015. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 526:263–267.

33. Vivanco, I., D. Rohle, M. Versele, A. Iwanami, D. Kuga, B. Oldrini, et al. 2010. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci U S A 107: 6459–6464.

34. de la Rochefordiere, A., M. Kamal, A. Floquet, L. Thomas, P. Petrov, T. Petit, et al. 2015. PIK3CA pathway mutations predictive of poor response following standard radiochemotherapy ± cetuximab in cervical cancer patients. Clin. Cancer Res. 21:2530–2537.

35. Huang, L., and L. Fu. 2015. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm. Sin. B2015 5:390–401.

36. Aljoljani, H., R. F. Koncar, A. Zarzour, B. S. Park, S. H. Lee, and E. M. Bahassi. 2015. ROS1 amplification mediates resistance to gefitinib in glioblastoma cells. Oncotarget 6:20388–20395.

37. Chiang, N.-J., C. Hsu, J.-S. Chen, H.-H. Tsou, Y.-Y. Shen, Y. Chao, et al. 2016. Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer. Sci. Rep. 6:25369.

38. Kumar, B., K. G. Cordell, J. S. Lee, F. P. Worden, M. E. Prince, H. H. Tran, et al. 2008. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J. Clin. Oncol. 26:3128–3137.

39. Hong, A., T. Dobbins, C. S. Lee, D. Jones, E. Jackson, J. Clark, et al. 2010. Relationships between epidermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer. Eur. J. Cancer 46:2088–2096.

40. Lassen, P., J. Overgaard, and J. G. Eriksen. 2013. Expression of EGFR and HPV-associated p16 in oropharyngeal carcinoma: correlation and influence on prognosis after radiotherapy in the randomized DAHANCA 5 and 7 trials. Radiother. Oncol. 108:489–494.

41. Wong, N., W. Yeo, W.-L. Wong, N. L.-Y. Wong, K. Y.-Y. Chan, F. K.-F. Mo, et al. 2009. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int. J. Cancer 124:644–652.

42. Burgess, D. J., J. Doles, L. Zender, W. Xue, B. Ma, W. R. Mccombe, et al. 2008. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A 2008. 105:9053–9058.

43. Braun, M. S., S. D. Richman, P. Quirke, C. Daly, J. W. Adlard, F. Elliott, et al. 2008. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J. Clin. Oncol. 26:2690–2698.

44. Nygard, S. B., B. Vainer, S. L. Nielsen, F. Bosman, S. Tejpar, A. Roth, M. Delorenzi, N. Brunner, and E. Budinska. 2016. DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer. Clin Cancer Res 22:1621–31.

45. Phan, L. K., and P. M. Hoff. 2007. Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Dis. Colon Rectum 50:395–398.

46. Lukan, N., P. Ströbel, A. Willer, M. Kripp, D. Dinter, S. Mai, et al. 2009. Cetuximab- based treatment of oropharyngeal cancer: report of a case. Dis. Colon Rectum 52:263–267.

47. Rose, P. G., J. A. Blessing, L. Van Le, and S. Waggoner. 1998. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol. Oncol. 70:263–266.

48. Reed, E. 2005. ERCC1 and clinical resistance to platinum-based therapy. Clin. Cancer Res. 11:6100–6102.

49. Chiu, T.-J., C.-H. Chen, C.-Y. Chien, S.-H. Li, H.-T. Tsai, Y.-J. Chen, et al. 2011. High ERCC1 expression predicts...
cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area. J. Transl. Med. 9:31.

50. Britten, R. A., D. Liu, A. Tessier, M. J. Hutchison, and D. Murray. 2000. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int. J. Cancer 89:453–457.

51. Al-Minawi, A. Z., Y.-F. Lee, D. Håkansson, F. Johansson, C. Lundin, N. Saleh-Gohari, et al. 2009. The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links. Nucleic Acids Res. 37:6400–6413.

52. Cheng, H., Z. Zhang, A. Borczuk, C. A. Powell, A. S. Balajee, H. B. Lieberman, et al. 2013. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. Carcinogenesis 34:739–749.

53. Woll, P. J., I. Judson, S. M. Lee, S. Rodenhuis, O. S. Nielsen, J. M. Buesa, et al. 1999. Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 35:410–412.

54. Shacham-Shmueli, E., A. Beny, R. Geva, A. Blachar, A. Figer, and D. Aderka. 2011. Response to temozolomide in patients with metastatic colorectal cancer with loss of mgmt expression: a new approach in the era of personalized medicine? J. Clin Oncol. 29:e262–e265.

55. Villaruz, L. C., and M. A. Socinski. 2016. The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy. Clin. Pharmacol. Ther. 100:212–214.

56. Yang, W., Y. Song, Y. L. Lu, J. Z. Sun, and H. W. Wang. 2013. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia. Immunology 139:513–522.

57. Lyford-Pike, S., S. Peng, G. D. Young, J. M. Taube, W. H. Westra, B. Akpeng, et al. 2013. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res. 73:1733–1741.

Supporting Information

Additional supporting information may be found in the online version of this article:

Figure S1. Protein expression does not significantly differ between primary and metastatic tumors. Tumors from the primary and metastatic sites were compared for expression of proteins for which data were available for all four type of SCC. For ASCC \( n \geq 25 \) (primary) and \( n \geq 35 \) (metastatic). For CSCC \( n \geq 42 \) (primary) and \( n \geq 72 \) (metastatic). For OSCC \( n \geq 22 \) (primary) and \( n \geq 28 \) (metastatic). For VSCC \( n \geq 15 \) (primary) and \( n \geq 12 \) (metastatic).

Table S1. Probe and Threshold information for IHC and ISH

Table S2. P16 expression status of OSCC patient samples determined by IHC.

Table S3. Targeted sequencing results for patient samples tested.

Table S4. Summary of IHC, ISH, and sequencing results for each patient sample.